ABSTRACT:
With the establishment of 12 regional centers, India implemented a comprehensive system for monitoring drug reactions in 1986. In 1997, India became a member of the Uppsala Monitoring Centre in Sweden, which oversees the World Health Organization's Programme for International Drug Surveillance. Beginning at the outset, six regional centers were created in Chandigarh, New Delhi, Mumbai, Kolkata, Lucknow, and Pondicherry. ADR is being watched throughout the nation. Advocating for safe drug use may become a top focus for the Indian Pharmacopoeia Commission, which also functions as the National Coordination Centre for India's Pharmacovigilance Program. We currently have 179 adverse drug reactions under observation. At the moment, the National Coordination Centre receives adverse event reports from centers in India.Reporting Form; Phocomelia; Vigiflow; UMC; Death; Thalidomide
Cite this article:
Goswami Raksha, Kaushal Rakhi, Kumawat Deepak, Ahirwar Mamta. Ensuring Medication Safety in India: The Crucial Role of the Pharmacovigilance Programme of India (PvPI) in Adverse Drug Event Monitoring. Research Journal of Science and Technology. 2024; 16(2):159-2. doi: 10.52711/2349-2988.2024.00023
Cite(Electronic):
Goswami Raksha, Kaushal Rakhi, Kumawat Deepak, Ahirwar Mamta. Ensuring Medication Safety in India: The Crucial Role of the Pharmacovigilance Programme of India (PvPI) in Adverse Drug Event Monitoring. Research Journal of Science and Technology. 2024; 16(2):159-2. doi: 10.52711/2349-2988.2024.00023 Available on: https://rjstonline.com/AbstractView.aspx?PID=2024-16-2-8
REFERENCES:
1. "Targeted Pharmacovigilance Study on Antitubercular Drugs in the Department of Pulmonary Medicine at Tertiary Care Teaching Hospital in Rural Area," by Nimesh S and Prem Parkash KA. 1-6 in International Journal of Pharmacovigilance (2019)."Targeted Pharmacovigilance Study on Antitubercular Drugs in the Department of Pulmonary Medicine at Tertiary Care Teaching Hospital in Rural Area," by Nimesh S and Prem Parkash KA. 1-6 in International Journal of Pharmacovigilance (2019).
2. "Pharmacovigilance: An Overview," by Nimesh S and Ashwlayan VD. 1-6 in International Journal of Pharmacovigilance, vol. 3.1, 2018.
3. "Directorate General of Health Services, Ministry of Health and Family Welfare." 3. Central TB Division.
4. India, TB 2006. Report on the status of RNTCP. MFHW, New Delhi, India (2006).
5. The National Library of Medicine of the United States of America. APIs for RxNorm. Obtainable from (2017).
6. Srivastava, S. K. "A comprehensive textbook of medical pharmacology," 1st edition, Chapter 56 (2017) 888, Srivastava, S. K. "A full textbook of medical pharmacology," 1st edition, Chapter 56 (2017) 888, Srivastava
7. The Bio-Medical Waste Management (Amendment) Rules are a set of rules that govern the management of bio-medical waste (2018).
8. "Prevalence and Extent of Adverse Drug Reactions in Sudanese Patients on Highly Active Antiretroviral Therapy Regimens." Mohamed B Elnagar I. 1-12 in International Journal of Pharmacovigilance, Vol. 2.2 (2017).
9. "Selective upper airway stimulation in elderly patients," Zhu Z., et al. 77-81 in Respiratory Medicine 140 (2018).